Tvardi Therapeutics is trading higher at $1.04, up 10.64% in after-hours trading following the October 23 session, with no clear catalyst identified.
- Its latest listed press release, dated October 14, announced a conference appearance; it does not establish a reason for this move.
- Recent coverage mentions earlier analyst activity and clinical-program updates, not a new October 23 announcement.
- Broader market performance was mixed, and available evidence does not point to a specific company, sector, or global explanation.